Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia

Schizophrenia Research

Volumn 70, Issue 2-3, 2004, Pages 263-275

  Dolan, Sara L ^a   Sacco, Kristi A ^a   Termine, Angelo ^a   Seyal, Aisha A ^a   Dudas, Melissa M ^a   Vessicchio, Jennifer C ^a   Wexler, Bruce E ^a   George, Tony P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive deficits; Neuropsychological function; Nicotine dependence; Prefrontal cortex; Schizophrenia; Smoking cessation

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; PLACEBO; SELEGILINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MENTAL PATIENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; SYMPTOM; TASK PERFORMANCE; TREATMENT FAILURE; WISCONSIN CARD SORTING TEST; WORKING MEMORY;

COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT FAILURE;

EID: 4344717730     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.01.006     Document Type: Article

References (66)

1. Abbott M.W., Gregaon R.A.M. Cognitive dysfunction in the prediction of relapse in alcoholics. Journal of Studies on Alcohol. 42:1981;230-243
2. Addington J., el-Guebaly N., Campbell W., Hodgins D.C., Addington D. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry. 155:1998;974-976
3. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry. 150:1993;1856-1861
4. Adler L.E., Hoffer L.D., Waldo M., et al. Schizophrenia, sensory gating and nicotinic receptors. Schizophrenia Bulletin. 24:1998;189-202
5. Bell M., Bryson G., Tamasine G., Corcoran C., Wexler B.E. Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance. Archives of General Psychiatry. 58:2001;763-768
6. Burgess E.S., Brown R.A., Kahler C.W., Niaura R., Abrams D.B., Goldstein M.G., Miller I.W. Patterns of change in depressive symptoms during smoking cessation: who's at risk for relapse? Journal of Consulting and Clinical Psychology. 70:2002;356-361
7. Carter C.S., Braver T.S., Barch D.M., Botvinick M., Noll D., Cohen J.D. Anterior cingulate cortex, error detection, and the on line monitoring of performances. Science. 280:1998;747-749
8. CDC Cigarette smoking among adults in the United States, 2002. Morbidity and Mortality World Report. 51:2002;300-303
9. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1988;Lawrence Erlbaum Associates, Hillsdale, NJ
10. Connors C.K. The Continuous Performance Test (CPT). 1995;Psychological Assessment Resources, Odessa, FL
11. Davidson M., Keefe R.S.E. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research. 17:1995;123-129
12. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;6917-6922
13. Evins A.E., Mays V.K., Rigotti N.A., Tisdale T., Cather C., Goff D.C. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine & Tobacco Research. 3:2001;397-403
14. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;587-592
15. Friedman J.I., Temporini H., Davis K.L. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry. 45:1999;1-16
16. George T.P., Vessicchio J.C. Treating tobacco addiction in schizophrenia: where do we go from here? Addiction. 97:2002;795-796. (commentary)
17. George T.P., Verrico C.D., Picciotto M.R., Roth R.H. Nicotinic modulation of mesoprefrontal dopamine systems: pharmacologic and neuroanatomic characterization. Journal of Pharmacology and Experimental Therapeutics. 295(1):2000;58-66
18. George T.P., Zeidonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry. 157(11):2000;1835-1842
19. George T.P., Seyal A.A., Dolan S.L., Dudas M.M., Termine A., Vessicchio J.C. Nicotine addiction and schizophrenia: a clinical approach. Primary Psychiatry. 9(11):2002;48-53
20. George T.P., Vessicchio J.C., Termine A., Bregartner T.A., Feingold A., Rounsaville B.J., Kosten T.R. A placebo-controlled study of bupropion for smoking cessation in schizophrenia. Biological Psychiatry. 52:2002;53-61
21. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 26:2002;75-85
22. George T.P., Vessicchio J.C., Termine A., Jatlow P.I., Kosten T.R., O'Malley S.S. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biological Psychiatry. 53:2003;136-143
23. Glassman A.H., Covey L.S., Dalack G.W., Stetner F., Rivelli S.K., Fleiss J., et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology and Therapeutics. 54(6):1993;670-679
24. Glassman A.H., Covey L.S., Stetner F., Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 357:2001;1929-1932
25. Goldberg T.F., Weinberger D.R. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophrenia Research. 14:1988;179-183
26. Goldman R.S., Goldman M.S. Experience-dependent cognitive recovery in alcoholics: a task component strategy. Journal of Studies on Alcohol. 49:1988;142-148
27. Goldman-Rakic P.S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biological Psychiatry. 46:1999;650-661
28. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry. 153(3):1996;321-330
29. Green M.F., Marder S.R., Glynn S.M., McGurk S.R., Wirshing W.C., Wirshing D.A., Liberman R.P., Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological Psychiatry. 51:2002;972-978
30. Gur R.E., Cowell P.E., Latshaw A., Turetsky B.I., Grossman R.I., Arnold S.E., Bilker W.B., Gur R.C. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Archives of General Psychiatry. 57:2000;761-768
31. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry. 158:2001;176-184
32. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction. 86:1991;1119-1127
33. Heaton R.K., Chelune G.J., Talley J.L., et al. Wisconsin Card Sorting Test. Manual. 1993;Psychological Assessment Resources, Odessa, FL
34. Hepp H., Maier S., Hermle L., Spitzer M. The stroop effect in schizophrenic patients. Schizophrenia Research. 22:1996;187-195
35. Hughes J.R., Goldstein M.G., Hurt R.D., Shiffman S. Recent advances in the pharmacotherapy of smoking. Journal of the American Medical Association. 281:1999;72-76
36. Keefe R.S.E., Lees Roitman S.E., Harvey P.D., Blum C.S., DuPre R.L., Prieto R.M., Davidson M., Davis K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research. 17:1995;25-33
37. Kern R.S., Wallace C.J., Hellman S.G., Womack L.M., Green M.F. A training procedure for remediating WCST deficits in chronic psychotic patients: an adaptation of errorless learning principles. Journal of Psychiatric Research. 30:1996;283-294
38. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. Journal of Psychopharmacology. 11(2):1997;123-131
39. Lasser K., Boyd J.W., Woolhander S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. Journal of the American Medical Association. 284:2000;2606-2610
40. Lee M.A., Thompson P., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry. 55:1994;8-14
41. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophrenia Research. 37:1999;1-11
42. Levin E.D., Wilson W., Rose J., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996;429-436
43. Lezak M.D. Neuropsychological Assessment. 1995;Oxford Univ. Press, New York
44. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic drugs. American Journal of Psychiatry. 157:2000;767-771
45. McEvoy J., Freudenreich O., McGee M., VanderZwaag C., Levin E., Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry. 37:1995;550-552
46. McEvoy J.P., Freudenreich O., Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry. 46:1999;125-129
47. McGurk S.R., Green M.G., Wirshing W.C., Ames D., Marshall B.D., Marder S.M. The effects of risperidone versus haloperidol on spatial working memory in treatment-resistant schizophrenia. Paper presented at 51st Annual Meeting of the Society for Biological Psychiatry, New York, NY:1996
48. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin. 25:1999;233-255
49. Meltzer H.Y., Park S., Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proceedings of the National Academy of Sciences of the United States of America. 96(24):1999;13591-13593
50. Mialet J.P., Pope H.G., Yurgelun-Todd D. Impaired attention in depressive states: a non-specific deficit? Psychological Medicine. 26:1996;1009-1020
51. Morice R., Delahunty A. Frontal/executive impairments in schizophrenia. Schizophrenia Bulletin. 22:1996;125-137
52. Nagamoto H.T., Adler L.E., Waldo M.C., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biological Psychiatry. 40:1996;181-188
53. O'Leary M.R., Donovan D.M., Chaney E.F., Walker R.D. Cognitive impairment and treatment outcomes with alcoholics: preliminary findings. Journal of Clinical Psychiatry. 40:1979;397-398
54. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Archives of General Psychiatry. 49:1992;975-982
55. Postma P., Kumari V., Sharma T., Hines M., Gray J.A. Startle response during smoking and 24 h after withdrawal predicts successful smoking cessation. Psychopharmacology. 156:2001;360-367
56. Procyshyn R.M., Ihsan N., Thompson D. A comparison of smoking behaviors between patients treated with clozapine and depot neuroleptics. International Clinical Psychopharmacology. 16:2001;291-294
57. Procyshyn R.M., Tse G., Sin O., Flynn S. Concomitant clozapine reduces smoking in patients treated with risperidone. European Neuropsychopharmacology. 12:2002;77-80
58. Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C, Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Nicotinic receptor mechanisms and neuropsychological function in schizophrenia: effects on spatial working memory and attention. American College of Neuropsychopharmacology, 42nd Annual Meeting, San Juan, Puerto Rico:2003
59. Schlaepfer T.E., Harris G.J., Tien A.Y., Peng L.W., Lee S., Federman E.B., Chase G.A., Barta P.E., Pearlson G.D. Decreased regional cortical gray matter volume in schizophrenia. American Journal of Psychiatry. 151:1994;842-848
60. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 27:2002;479-497
61. Sullivan E., Lim K., Mathalon D., Marsh L., Beal D., Harris D., Hoff A., Faustman W., Pfefferbaum A. A profile of cortical gray matter volume deficits characteristic of schizophrenia. Cerebral Cortex. 8:1998;117-124
62. Termine A., Vessicchio J.C., Seyal A.A., Dolan S.L., Krishnan-Sarin S., Wexler B.E., George T.P. Nicotinic receptor mechanisms and cognitive function in schizophrenia. Abstracts-Society for Neuroscience. 32:2002;2861
63. Weiner E., Ball M.P., Summerfelt A., Gold J., Buchanan R.W. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. American Journal of Psychiatry. 158(4):2001;635-637
64. Wexler B.E., Hawkins K.A., Rounsaville B.J., Anderson M., Sernyak M.J., Green M.F. Normal neurocognitive performance after extended practice in patients with schizophrenia. Schizophrenia Research. 26:1997;173-180
65. Wexler B.E., Anderson M., Fulbright R.K., Gore J.C. Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises. American Journal of Psychiatry. 157:2000;1694-1697
66. Wykes T., Brammer M., Mellers J., Bray P., Reeder C., Williams C., Corner J. Effects on the brain of a psychological treatment: cognitive remediation therapy. Functional magnetic resonance imaging in schizophrenia. British Journal of Psychiatry. 181:2002;144-152